Clinical Trial

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuzumab (T) emtansine (DM1) on cancer recurrence.
Protocol Amendment History 1 change
notable Enrollment reduced: 55 -> 37 participants 2026-04-14
Trial Details
NCT Number NCT04620187
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Genentech, Inc.
Conditions Salivary Gland Cancer, HER2 Gene Mutation
Enrollment 37 participants
Start Date 2020-12-24
Primary Completion 2028-02-01 (estimated)
Study Completion 2029-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-13